Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences Corp. (EW)
:EW
Holding EW?
Track your performance easily
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $96.12
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.92M
Market Cap
$41.20B
Enterprise Value$35.79B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$822.30M
Price to Earnings (P/E)10.1
Beta1.32
Next Earnings
Jan 30, 2025EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.93
Shares Outstanding589,800,000
10 Day Avg. Volume4,096,737
30 Day Avg. Volume4,915,269
Standard Deviation0.10
R-Squared0.36
Alpha-0.00869
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.02
Price to Cash Flow (P/CF)29.30
P/FCF Ratio32.30
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue6.09
Enterprise Value/Gross Profit7.74
Enterprise Value/Ebitda21.99
Forecast
1Y Price Target
$77.75Price Target Upside11.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEdwards Lifesciences Corp. is expecting average 10% revenue growth and double-digit EPS growth in 2026 and beyond.
Growth OpportunitiesThe expansion of the TAVR national coverage determination to include a less-severe population is a key catalyst for growth.
Innovation And Product DevelopmentManagement expects a strong cadence of innovation and data to drive momentum, including TAVR growth of mid-to-high single digits driven by changes to guidelines and capacity expansion.
Bears Say
Competitive LandscapeThere is limited visibility on Edwards Lifesciences' core TAVR business due to ongoing capacity constraints and an increasingly competitive landscape.
Foreign Exchange ImpactEdwards Lifesciences Corp. anticipates a $100M foreign exchange headwind impacting revenue.
Product Adoption ChallengesThe biggest headwinds for Evoque adoption relate to the system's newness and high price, followed by the availability of a more familiar and less expensive repair option, ABT's TriClip.
---
Ownership Overview
0.93% Insiders
21.33% Mutual Funds
1.79% Other Institutional Investors
52.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences Corp.’s price range in the past 12 months?
Edwards Lifesciences Corp. lowest stock price was $58.93 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences Corp.’s market cap?
Edwards Lifesciences Corp.’s market cap is $41.20B.
When is Edwards Lifesciences Corp.’s upcoming earnings report date?
Edwards Lifesciences Corp.’s upcoming earnings report date is Jan 30, 2025 which is in 9 days.
How were Edwards Lifesciences Corp.’s earnings last quarter?
Edwards Lifesciences Corp. released its earnings results on Oct 24, 2024. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.665 by $0.005.
Is Edwards Lifesciences Corp. overvalued?
According to Wall Street analysts Edwards Lifesciences Corp.’s price is currently Undervalued.
Does Edwards Lifesciences Corp. pay dividends?
Edwards Lifesciences Corp. does not currently pay dividends.
What is Edwards Lifesciences Corp.’s EPS estimate?
Edwards Lifesciences Corp.’s EPS estimate is 0.55.
How many shares outstanding does Edwards Lifesciences Corp. have?
Edwards Lifesciences Corp. has 589,800,000 shares outstanding.
What happened to Edwards Lifesciences Corp.’s price movement after its last earnings report?
Edwards Lifesciences Corp. reported an EPS of $0.67 in its last earnings report, beating expectations of $0.665. Following the earnings report the stock price went down -1.379%.
Which hedge fund is a major shareholder of Edwards Lifesciences Corp.?
Currently, no hedge funds are holding shares in EW
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.75 (11.42% Upside)
$77.75 (11.42% Upside)
Blogger Sentiment
Bullish
EW Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 916.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $170.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.47%
12-Months-Change
Fundamentals
Return on Equity
17.93%
Trailing 12-Months
Asset Growth
38.42%
Trailing 12-Months
Company Description
Edwards Lifesciences Corp.
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant growth in key segments like TMTT and surgical operations. However, challenges such as capacity constraints and market pressures in specific regions temper the outlook. Overall, the positive aspects slightly outweigh the negatives, indicating steady strategic progress and strong financial performance.Read More>---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$77.75
▲(11.42% Upside)
Technical Analysis
Boston Scientific
―
Medtronic
―
Baxter International
―
Stryker
―
Intuitive Surgical
―
Zimmer Biomet Holdings
―
Best Analysts Covering EW
1 Year
1 Year Success Rate
22/32 ratings generated profit
1 Year Average Return
+11.45%
reiterated a buy rating 2 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +11.45% per trade.
---